Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Looks To Combination Regimens To Maximize Oncology Pipeline Value

Executive Summary

Pfizer is seeking to maximize the value of its oncology pipeline by developing combination regimens, Senior VP-Worldwide Development Declan Doogan said Nov. 30
Advertisement

Related Content

Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer
Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer
Pfizer Better Able To De-Risk First-In-Class Compounds, R&D Head Says
Pfizer Better Able To De-Risk First-In-Class Compounds, R&D Head Says
Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations
Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations
What’s Old Is New Again: Bristol Cancer Plans Re-Emphasize Cytotoxics
Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Advertisement
UsernamePublicRestriction

Register

PS047832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel